Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYPH Cypherpunk Technologies	$0.65 -4.1%	$0.97	$0.23 ▼ $3.70	$72.15M	-0.02	7.35 million shs	2.41 million shs
GANX Gain Therapeutics	$1.68 -0.6%	$1.84	$1.41 ▼ $4.34	$72.08M	0.16	713,001 shs	482,863 shs
SXTC China SXT Pharmaceuticals	$2.57 +13.7%	$1.84	$1.25 ▼ $1,046.98	$86.37M	1.91	122,818 shs	161,335 shs
XCUR Exicure	$2.78 -1.4%	$3.37	$2.62 ▼ $9.50	$17.98M	3.53	16,423 shs	24,924 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYPH Cypherpunk Technologies	+2.99%	-30.95%	-36.66%	+16.84%	+55.47%
GANX Gain Therapeutics	+3.05%	-9.14%	-6.11%	-30.45%	-5.59%
SXTC China SXT Pharmaceuticals	+28.41%	+43.95%	+41.25%	+19.58%	-99.23%
XCUR Exicure	+2.17%	-4.73%	-12.96%	-32.86%	-69.81%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYPH Cypherpunk Technologies	$0.65 -4.1%	$0.97	$0.23 ▼ $3.70	$72.15M	-0.02	7.35 million shs	2.41 million shs
GANX Gain Therapeutics	$1.68 -0.6%	$1.84	$1.41 ▼ $4.34	$72.08M	0.16	713,001 shs	482,863 shs
SXTC China SXT Pharmaceuticals	$2.57 +13.7%	$1.84	$1.25 ▼ $1,046.98	$86.37M	1.91	122,818 shs	161,335 shs
XCUR Exicure	$2.78 -1.4%	$3.37	$2.62 ▼ $9.50	$17.98M	3.53	16,423 shs	24,924 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYPH Cypherpunk Technologies	+2.99%	-30.95%	-36.66%	+16.84%	+55.47%
GANX Gain Therapeutics	+3.05%	-9.14%	-6.11%	-30.45%	-5.59%
SXTC China SXT Pharmaceuticals	+28.41%	+43.95%	+41.25%	+19.58%	-99.23%
XCUR Exicure	+2.17%	-4.73%	-12.96%	-32.86%	-69.81%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYPH Cypherpunk Technologies	1.00	Sell	N/A	N/A
GANX Gain Therapeutics	2.67	Moderate Buy	$8.50	401.47% Upside
SXTC China SXT Pharmaceuticals	1.00	Sell	N/A	N/A
XCUR Exicure	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest XCUR, GANX, CYPH, and SXTC Analyst Ratings

Date	Company	Brokerage	Action	Rating
6/9/2026	GANX Gain Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/5/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
5/28/2026	XCUR Exicure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/27/2026	GANX Gain Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
5/21/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D-)
5/19/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
5/12/2026	GANX Gain Therapeutics	Roth Mkm Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/1/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
4/22/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
4/10/2026	GANX Gain Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	$1.83 per share	N/A
GANX Gain Therapeutics	$50K	1,445.84	N/A	N/A	$0.48 per share	3.53
SXTC China SXT Pharmaceuticals	$1.74M	54.58	N/A	N/A	$3,187.45 per share	0.00
XCUR Exicure	$500K	35.61	N/A	N/A	$0.62 per share	4.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYPH Cypherpunk Technologies	$4.82M	-$0.02	N/A	N/A	N/A	N/A	-48.33%	-42.21%	N/A
GANX Gain Therapeutics	-$20.16M	-$0.58	N/A	N/A	N/A	N/A	-201.44%	-136.24%	8/11/2026 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.30M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XCUR Exicure	-$4.95M	-$1.55	N/A	N/A	N/A	N/A	-179.41%	-64.37%	8/7/2026 (Estimated)

Latest XCUR, GANX, CYPH, and SXTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2026	Q1 2026	XCUR Exicure	-$18.60	-$0.29	+$18.31	-$0.29	$1.64 million	N/A
5/14/2026	Q1 2026	CYPH Cypherpunk Technologies	-$0.0406	-$0.46	-$0.4194	-$0.46	N/A	N/A
5/11/2026	Q1 2026	GANX Gain Therapeutics	-$0.13	-$0.13	N/A	-$0.13	$0.03 million	N/A
3/26/2026	Q4 2025	GANX Gain Therapeutics	-$0.14	-$0.11	+$0.03	-$0.11	$0.03 million	N/A
3/25/2026	Q4 2025	XCUR Exicure	-$18.60	-$0.46	+$18.14	-$0.46	$1.64 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	N/A
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XCUR Exicure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYPH Cypherpunk Technologies	N/A	27.28	27.28
GANX Gain Therapeutics	0.02	4.69	4.69
SXTC China SXT Pharmaceuticals	N/A	4.37	4.24
XCUR Exicure	N/A	0.79	0.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYPH Cypherpunk Technologies	30.46%
GANX Gain Therapeutics	11.97%
SXTC China SXT Pharmaceuticals	5.02%
XCUR Exicure	42.82%

Insider Ownership

Company	Insider Ownership
CYPH Cypherpunk Technologies	3.50%
GANX Gain Therapeutics	4.15%
SXTC China SXT Pharmaceuticals	3.95%
XCUR Exicure	52.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYPH Cypherpunk Technologies	40	106.46 million	102.74 million	Optionable
GANX Gain Therapeutics	20	42.65 million	40.88 million	Optionable
SXTC China SXT Pharmaceuticals	90	38.22 million	36.71 million	Not Optionable
XCUR Exicure	50	6.37 million	3.01 million	Not Optionable

XCUR, GANX, CYPH, and SXTC Headlines

Recent News About These Companies

Exicure, Inc.: Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

June 11 at 8:51 AM | finanznachrichten.de

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement

June 10 at 7:40 PM | markets.businessinsider.com

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

June 10 at 4:01 PM | globenewswire.com

Exicure Regains Nasdaq Compliance After Late Quarterly Filing

June 1, 2026 | tipranks.com

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

June 1, 2026 | globenewswire.com

Exicure delays quarterly filing, trims quarterly loss

May 15, 2026 | tipranks.com

Exicure, Inc. and Adbiotech Co., Ltd. Announce Co-Development Agreement for Burixafor Combination Therapies

April 22, 2026 | quiverquant.comQ

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

April 22, 2026 | globenewswire.com

Exicure Inc.

April 13, 2026 | barrons.com

Exicure Strengthens Leadership With New COO and Director

April 10, 2026 | tipranks.com

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

April 2, 2026 | globenewswire.com

Exicure, Inc. Reports 2025 Financial Results and Announces Need for Additional Financing

March 25, 2026 | quiverquant.comQ

Exicure, Inc. Reports 2025 Financial Results and Highlights Need for Additional Financing

March 25, 2026 | quiverquant.comQ

Exicure, Inc. Reports Full Year 2025 Financial Results

March 25, 2026 | globenewswire.com

Exicure, Inc. Reports Full Year 2025 Financial Results

March 25, 2026 | globenewswire.com

Exicure, Inc. Publishes Phase 2 Study Results for Burixafor, a Novel CXCR4 Inhibitor in Hematologic Disease Treatment

February 5, 2026 | quiverquant.comQ

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

February 5, 2026 | globenewswire.com

Exicure, Inc. to Present Phase 2 Trial Results for Burixafor at 2026 ASTCT and CIBMTR Tandem Meetings

January 21, 2026 | quiverquant.comQ

Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

January 21, 2026 | globenewswire.com

Sangsangin Investment & Securi Sells 433,332 Shares of Exicure (NASDAQ:XCUR) Stock

December 11, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR, GANX, CYPH, and SXTC Company Descriptions

Cypherpunk Technologies NASDAQ:CYPH

$0.65 -0.03 (-4.06%)

As of 04:00 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Gain Therapeutics NASDAQ:GANX

$1.68 -0.01 (-0.59%)

Closing price 04:00 PM Eastern

Extended Trading

$1.72 +0.04 (+2.32%)

As of 06:00 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

China SXT Pharmaceuticals NASDAQ:SXTC

$2.57 +0.31 (+13.72%)

Closing price 04:00 PM Eastern

Extended Trading

$2.52 -0.05 (-1.95%)

As of 07:57 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Exicure NASDAQ:XCUR

$2.78 -0.04 (-1.42%)

Closing price 04:00 PM Eastern

Extended Trading

$2.70 -0.07 (-2.70%)

As of 04:36 PM Eastern

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XCUR, GANX, CYPH, and SXTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XCUR, GANX, CYPH, and SXTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XCUR, GANX, CYPH, and SXTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR, GANX, CYPH, and SXTC Company Descriptions

Cypherpunk Technologies NASDAQ:CYPH

Gain Therapeutics NASDAQ:GANX

China SXT Pharmaceuticals NASDAQ:SXTC

Exicure NASDAQ:XCUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XCUR, GANX, CYPH, and SXTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XCUR, GANX, CYPH, and SXTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XCUR, GANX, CYPH, and SXTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR, GANX, CYPH, and SXTC Company Descriptions

Cypherpunk Technologies NASDAQ:CYPH

Gain Therapeutics NASDAQ:GANX

China SXT Pharmaceuticals NASDAQ:SXTC

Exicure NASDAQ:XCUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools